Climb Bio, Inc.
CLYM Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$10.19
KIRA · Stoqly’s AI analyst, in plain words
- Climb Bio, Inc. lost $59.9M in fiscal 2025.
- Free cash flow was −$54.5M in fiscal 2025, — of revenue.
Market cap
$776M
P/E
—
Revenue
—
Net income
−$59.9M
Free cash flow
−$54.5M
Operating margin
—
Climb Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$59.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Climb Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Climb Bio, Inc.
- CIK
- 0001768446
Climb Bio, Inc. · CLYM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$47.5M | −$45.2M | −$35.1M | −$73.9M | −$59.9M |
| Diluted EPS | −$4.24 | −$1.72 | −$1.30 | −$1.53 | −$0.88 |
| Cash | |||||
| Cash from operations | −$36.1M | −$37.4M | −$20.6M | −$15.6M | −$54.4M |
| Capital expenditure | — | — | $0.0M | $0.0M | $0.2M |
| Free cash flow | — | — | −$20.6M | −$15.6M | −$54.5M |
| Share count change | 460.4% | 114.6% | 2.6% | 78.5% | 40.8% |
| Debt and strength | |||||
| Cash and short-term investments | $136M | $124M | $107M | $151M | $101M |
| Shareholders' equity | $167M | $129M | $108M | $212M | $160M |
| Current ratio | 24.6x | 22.0x | 38.9x | 31.4x | 15.2x |
| Returns and quality | |||||
| Return on equity | −66.8% | −30.6% | −29.7% | −46.3% | −32.1% |
| Return on tangible equity | −31.1% | −35.2% | −32.6% | −34.9% | −37.3% |
| Altman Z'' | 31.7 | 22.6 | 38.7 | 40.5 | 18.7 |
Insiders bought, 12 months
$0.8M
2 insiders
Insiders sold, 12 months
$2.7M
2 insiders
Of sales under plans
100%
$2.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Climb Bio, Inc. · CLYM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.19 a share, the company is worth $776M.
Source: SEC EDGAR XBRL filings (CIK 0001768446). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.